Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

RaKa82 Jul. 10 at 4:03 PM

$IMNN having watched this again, I think Stacy telegraphed that some sort of partnership/deal will be announced soon. You only “respond to requests for information” if you’re actively working on a deal and if you’re on a CDA

0 · Reply

bxp2390 Jul. 10 at 1:57 PM

$IMNN They keep talking about a non-US company with whom there are ongoing discussions, wonder which it could be. Japan has a bunch of pharmas with possible interest in ovarian. Problem here is chicken and egg. Partnership dollars with rev share make little sense when a potential partner can acquire outright and own 100% of future revs. Lot easier for partnerships at much higher caps than lower caps, this is probably what they're finding out. At lower caps an outright sale is possibly the only option.

0 · Reply

ZacksSCR Jul. 9 at 8:04 PM

$IMNN @OTCMarkets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD https://buff.ly/GWnfdNK

0 · Reply

TheManUpstairs Jul. 8 at 2:30 PM

$IMNN update

1 · Reply

bxp2390 Jul. 8 at 1:37 PM

$IMNN Forms 4's look promising. Let's see if the insiders hold onto these or sell. CEO now inching toward 100k shares after such a long time. Double digits can make her a paper millionaire so some incentives in place finally. But wait for high information support here before getting in, don't trust the current setup unless we find a partner or major cancer site like sloan kettering or such that wants to come on board for P3.

1 · Reply

ConcernedCitizen23 Jul. 8 at 1:23 PM

$IMNN insiders getting stock in very other day…yeah I think we’re going up

0 · Reply

LongBallBarn Jul. 8 at 12:54 PM

$SYRA $TENX $VTVT $IMNN

0 · Reply

jjegglie Jul. 7 at 9:05 PM

$IMNN The market is heavily discounting the fact that the p2 numbers were flawed AND statistically insignificant. Furthermore, everyone has known for years that celsion and its corrupt management is running a dilution scam.

0 · Reply

bxp2390 Jul. 7 at 2:08 PM

$IMNN An 8 million market cap for a Phase 3 company with an ovarian cancer treatment is unheard of. Either this is the biggest deal in the market, or there is something the market is heavily discounting here. AFAIC we on the message board (however strongly we tout our views) are low information people. The high information people are researchers and other pharma companies. If there is anything that suggests that high information people feel this is a good deal then - and perhaps only then - the stock will take off. Until then...,

1 · Reply

LKDOG Jul. 6 at 5:57 PM

$IMNN Added 500 shares

0 · Reply

Imunon interim CFO Jeffrey Church to retire, Josh Blacher to succeed

Jun 25, 2026, 12:00 PM EDT - 15 days ago

Imunon Transcript: Life Sciences Virtual Investor Forum

Jun 25, 2026, 12:00 PM EDT - 15 days ago

Imunon Slides: Life Sciences Virtual Investor Forum

2026-06-23T12:28:48.000Z - 17 days ago

Imunon announces IDMC recommendation for continuation of OVATION 3 trial

Jun 23, 2026, 8:00 AM EDT - 17 days ago

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

Jun 22, 2026, 4:15 PM EDT - 17 days ago

IMUNON to Present at the Life Sciences Investor Forum on June 25th

Jun 16, 2026, 10:00 AM EDT - 24 days ago

Imunon Transcript: AGM 2026

Jun 4, 2026, 8:00 AM EDT - 5 weeks ago

IMUNON Announces Up to $10 Million Cash Financing

2026-05-12T16:03:21.000Z - 2 months ago

Imunon reports Q1 EPS (84c), consensus ($1.28)

May 12, 2026, 11:00 AM EDT - 2 months ago

Imunon Earnings Call Transcript: Q1 2026

May 12, 2026, 11:00 AM EDT - 2 months ago

Imunon Earnings release: Q1 2026

May 12, 2026, 11:00 AM EDT - 2 months ago

Imunon Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 2 months ago

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 8:30 AM EDT - 2 months ago

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Imunon Proxy statement: Proxy filing

2026-04-17T12:46:27.000Z - 3 months ago

Imunon initiated with a Buy at Maxim

Mar 31, 2026, 11:00 AM EDT - 3 months ago

Imunon Earnings Call Transcript: Q4 2025

Mar 31, 2026, 11:00 AM EDT - 3 months ago

Imunon Annual report: Q4 2025

Mar 31, 2026, 11:00 AM EDT - 3 months ago

Imunon Earnings release: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 3 months ago

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

2026-03-25T12:35:38.000Z - 3 months ago

Imunon announces final clinical data from OVATION 2 clinical trial

Mar 25, 2026, 8:05 AM EDT - 3 months ago

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

Mar 24, 2026, 8:00 AM EDT - 3 months ago

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

2026-02-05T13:21:18.000Z - 5 months ago

Imunon announces reorganization to eliminate headcount for Phase 3 trial

Feb 5, 2026, 8:05 AM EST - 5 months ago

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

2025-12-30T13:50:29.000Z - 6 months ago

Imunon prices 1.94M shares at $3.61 in registered direct offering

Dec 30, 2025, 8:30 AM EST - 6 months ago

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

2025-12-29T16:15:14.000Z - 6 months ago

Imunon CEO says ‘poised for key milestones’ as company enters 2026

Dec 29, 2025, 11:10 AM EST - 6 months ago

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Nov 13, 2025, 11:00 AM EST - 8 months ago

Imunon Earnings Call Transcript: Q3 2025

Nov 13, 2025, 11:00 AM EST - 8 months ago

Imunon Quarterly report: Q3 2025

Nov 13, 2025, 11:00 AM EST - 8 months ago

Imunon Earnings release: Q3 2025

2025-11-13T12:50:55.000Z - 8 months ago

Imunon reports Q3 EPS ($1.16) vs ($3.76) last year

2025-11-13T12:50:47.000Z - 8 months ago

Imunon expects cash to fund operations into Q1 of 2026

Nov 13, 2025, 7:45 AM EST - 8 months ago

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 1:30 PM EST - 8 months ago

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

2025-11-10T13:00:28.000Z - 8 months ago

Imunon showcases progress on IMNN-001 at R&D Day

Nov 10, 2025, 7:30 AM EST - 8 months ago

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Nov 7, 2025, 8:05 AM EST - 8 months ago

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Nov 6, 2025, 8:05 AM EST - 8 months ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Nov 4, 2025, 8:05 AM EST - 8 months ago

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

2025-10-30T12:21:17.000Z - 9 months ago

Imunon to present Phase 3 OVATION 3 study of IMNN-001

Oct 30, 2025, 8:00 AM EDT - 9 months ago

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

Oct 23, 2025, 10:01 AM EDT - 9 months ago

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Oct 20, 2025, 8:05 AM EDT - 9 months ago

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 17, 2025, 8:10 AM EDT - 9 months ago

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

2025-10-14T12:36:43.000Z - 9 months ago

Imunon to present Phase 3 OVATION trial of IMNN-001

Oct 14, 2025, 8:20 AM EDT - 9 months ago

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

2025-09-22T12:20:43.000Z - 10 months ago

Imunon: OVATION 2 study results reinforce IMNN-001 efficacy benefits

Sep 22, 2025, 8:05 AM EDT - 10 months ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

2025-09-19T12:10:26.000Z - 10 months ago

Imunon to present translational data from Phase 2 OVATION 2 Study of IMNN-001

Sep 19, 2025, 8:05 AM EDT - 10 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

2025-08-28T12:15:21.000Z - 11 months ago

Imunon regains compliance with Nasdaq min bid price listing requirement

Aug 28, 2025, 8:05 AM EDT - 11 months ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 1 year ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings Call Transcript: Q2 2025

Aug 5, 2025, 11:00 AM EDT - 1 year ago

Imunon Quarterly report: Q2 2025

Aug 5, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings release: Q2 2025

2025-08-05T12:16:44.000Z - 1 year ago

Imunon sees cash runway into 4Q25

2025-08-05T12:10:16.000Z - 1 year ago

Imunon reports Q2 EPS ($2.15), consensus ($4.99)

Aug 5, 2025, 8:00 AM EDT - 1 year ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-07-30T12:10:34.000Z - 1 year ago

Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001

Jul 30, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 1 year ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

2025-07-28T12:20:54.000Z - 1 year ago

Imunon board approves 15% stock dividend

Jul 28, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 1 year ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 1 year ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 1 year ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 12, 2025, 11:30 AM EDT - 1 year ago

Imunon Transcript: Life Sciences Investor Forum

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Imunon Proxy statement: Proxy Filing

Jun 3, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 1 year ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 30, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

Imunon Proxy statement: Proxy Filing

May 27, 2025, 8:05 AM EDT - 1 year ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 1 year ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 1 year ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 19, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing

May 15, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 13, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings Call Transcript: Q1 2025

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Quarterly report: Q1 2025

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings release: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 1 year ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Earnings Call Transcript: Q4 2024

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Annual report: Q4 2024

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Earnings release: Q4 2024

Feb 27, 2025, 8:05 AM EST - 1 year ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 1 year ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

RaKa82 Jul. 10 at 4:03 PM

0 · Reply

bxp2390 Jul. 10 at 1:57 PM

0 · Reply

ZacksSCR Jul. 9 at 8:04 PM

$IMNN @OTCMarkets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD https://buff.ly/GWnfdNK

0 · Reply

TheManUpstairs Jul. 8 at 2:30 PM

$IMNN update

1 · Reply

bxp2390 Jul. 8 at 1:37 PM

1 · Reply

ConcernedCitizen23 Jul. 8 at 1:23 PM

$IMNN insiders getting stock in very other day…yeah I think we’re going up

0 · Reply

LongBallBarn Jul. 8 at 12:54 PM

$SYRA $TENX $VTVT $IMNN

0 · Reply

jjegglie Jul. 7 at 9:05 PM

0 · Reply

bxp2390 Jul. 7 at 2:08 PM

1 · Reply

LKDOG Jul. 6 at 5:57 PM

$IMNN Added 500 shares

0 · Reply

Kingph31 Jul. 6 at 5:33 PM

$IMNN keep an eye on it. 🔥

1 · Reply

ConcernedCitizen23 Jul. 6 at 1:17 PM

$IMNN another phase 3 site opened!

1 · Reply

LabPsycho Jul. 4 at 9:05 PM

$IMNN I tried to share my concerns over a year ago...lots of red flags IMO

1 · Reply

jjegglie Jul. 1 at 11:32 PM

$IMNN A 7 figure salary for this new greaseball Blotcher, and still paying for Lurch. What a grift this company is!

0 · Reply

TheManUpstairs Jul. 1 at 9:27 AM

Well, well, well... So we’ve got fresh meat with a highly interesting resume stepping in as the new interim CFO. At $475/hour, $IMNN clearly isn't paying for bookkeeping (wink wink). With management recently talking about "ongoing discussions," "information requests," and "bigger pharma," the pieces are becoming increasingly interesting. mega

2 · Reply

jjegglie Jul. 1 at 2:28 AM

$IMNN Don't worry longs, Lurch the scumbag staying on as a 6 figure consultant to keep stealing from you.

0 · Reply

ConcernedCitizen23 Jun. 30 at 11:37 PM

$IMNN check the sec filings. All the executives just got 25,000 shares each. That means they think the price will run. I’m waiting for $100-250/share

0 · Reply

ConcernedCitizen23 Jun. 30 at 9:42 PM

$IMNN new cfo! This guy will get this company sold

0 · Reply

focafoca99 Jun. 30 at 8:55 PM

$IMNN swaps interim CFOs, with Jeffrey Church retiring and Josh Blacher taking over July 1. https://www.rapidticker.com/news/imnn-sec-filing-d42a4c

0 · Reply

jjegglie Jun. 29 at 6:10 PM

$IMNN I asked my own brain, because I possess both critical and analytic thinking skills, to document the evolution of celsion boilerplate fake drug promotion and dilution scam activity and there was no change detected. This is exactly the same as butter coated doxorubicin 1.9, 2.0, 3.0. Same management. Same press releases. Same financing sources. Same mindless retail bots who do no research.

2 · Reply

TheManUpstairs Jun. 29 at 4:51 PM

$IMNN soon

1 · Reply

BustdownBullie Jun. 27 at 11:06 AM

$IMNN how did we end up in this situation

2 · Reply

Market Cap	8.66M
Revenue (ttm)	0.00
Net Income (ttm)	-14.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	27,100
Avg Vol	58,244
Day's Range	N/A - N/A
Shares Out	4.20M
Stochastic %K	65%
Beta	1.96
Analysts	Strong Sell
Price Target	$17.00